{
  "id": 20444949,
  "title": "Cullinan Therapeutics at UBS conference: multiple catalysts ahead",
  "url": "https://urgent.news/2026/11/17/cullinan-therapeutics-at-ubs-conference-multiple-catalysts-ahead",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T14:43:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/cullinan-therapeutics-at-ubs-conference-multiple-catalysts-ahead-93CH-5033343"
  },
  "original_language": "en",
  "account": "Cullinan Therapeutics recently presented its portfolio of clinical-stage T-cell engagers at the UBS Global Biopharma Conference 2026. The company's focus spans immunology and oncology, with three key programs: CLN-978, CLN-049, and velinotamig.\n\nCLN-978, a CD19 T-cell engager, demonstrated early signs of deep B-cell depletion and remission in autoimmune diseases. Preliminary data from about 20 patients is anticipated in December. CLN-049, a FLT3 T-cell engager, achieved a 31% composite response rate in relapsed or refractory AML, and Phase II enrollment has commenced. Velinotamig, a BCMA T-cell engager, showed encouraging results in lupus, with responses at low doses and favorable cytokine release syndrome management.\n\nCullinan's CEO, Nadim Ahmed, expressed confidence in the company's leading portfolio and an exciting period ahead, with multiple milestones in the coming weeks and months. The company is targeting deeper remission, durability, safety, and patient selection for each program.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}